IQVIA Holdings Inc
NYSE:IQV

Watchlist Manager
IQVIA Holdings Inc Logo
IQVIA Holdings Inc
NYSE:IQV
Watchlist
Price: 199.39 USD -0.43% Market Closed
Market Cap: 36.2B USD
Have any thoughts about
IQVIA Holdings Inc?
Write Note

IQVIA Holdings Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IQVIA Holdings Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
IQVIA Holdings Inc
NYSE:IQV
PP&E Net
$772m
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
15%
Thermo Fisher Scientific Inc
NYSE:TMO
PP&E Net
$9.4B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
PP&E Net
$6B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
11%
West Pharmaceutical Services Inc
NYSE:WST
PP&E Net
$1.7B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
9%
Mettler-Toledo International Inc
NYSE:MTD
PP&E Net
$790.4m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
PP&E Net
$2B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
12%
No Stocks Found

IQVIA Holdings Inc
Glance View

Market Cap
36.2B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of healthcare, IQVIA Holdings Inc. emerges as a formidable player, seamlessly blending data analytics with the imperative of human well-being. Born from the merger of IMS Health and Quintiles in 2016, IQVIA stands at the intersection of technology and life sciences, leveraging vast amounts of health-related data to facilitate more informed decisions in drug development and patient care. The company's vast repository consists of a complex tapestry of dynamic insights from around the globe, which it transforms using sophisticated analytical tools. This technical prowess enables IQVIA to offer solutions that span clinical trials, health information services, and advanced analytics, creating substantial value for pharmaceutical and life sciences companies. At the heart of IQVIA’s revenue model lies its ability to provide strategic services that reduce the time and cost associated with the development of new pharmaceuticals. By offering an integrated suite of services from the initial phases of drug research to post-market monitoring, IQVIA assists its clients in navigating regulatory landscapes and commercializing their products effectively. Its expansive technological infrastructure does not just aid in drug development but also enhances patient engagement, creating digital pathways for more personalized healthcare solutions. Thus, IQVIA earns its keep by not only selling information but also by offering transformative insights that sharpen the competitive edge for its clients in the ever-evolving healthcare sector.

IQV Intrinsic Value
266.61 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is IQVIA Holdings Inc's PP&E Net?
PP&E Net
772m USD

Based on the financial report for Sep 30, 2024, IQVIA Holdings Inc's PP&E Net amounts to 772m USD.

What is IQVIA Holdings Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
15%

Over the last year, the PP&E Net growth was -2%. The average annual PP&E Net growth rates for IQVIA Holdings Inc have been -5% over the past three years , -4% over the past five years , and 15% over the past ten years .

Back to Top